<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76756">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106312</url>
  </required_header>
  <id_info>
    <org_study_id>N10DMY</org_study_id>
    <secondary_id>2588</secondary_id>
    <nct_id>NCT02106312</nct_id>
  </id_info>
  <brief_title>Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas</brief_title>
  <acronym>DOREMY</acronym>
  <official_title>Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the feasibility of reducing the dose of preoperative radiotherapy in MLS (Myxoid
      Liposarcomas) from 50 Gy to 36 Gy while maintaining comparable clinicopathological
      responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A Bayesian approach is considered for the analysis of this trial. The aim is to provide
           a stopping rule for inefficacy of the new dose.

        -  Two aspects are important to elucidate the mechanism of this treatment: dynamic
           investigations of perfusion and vasculature. Apart from participation to the dose
           reduction paragraphs of this study, patients will be also asked to undergo, at
           clinically relevant dose points, dynamic contrast enhanced (DEC) MRI scans and
           separately tumor biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Pathological description of the percentage necrosis after reduced RT (radiotherapy) dose from (conventionally) 25 x 2 Gy to 18 x 2 Gy (in the current study)</measure>
    <time_frame>The percentage of necrosis will be pathologically assessed on the resection specimen; this procedure will take on average 7-10 working days. After surgery, patients will be followed up to 10 years.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myxoid Liposarcoma of Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>dose reduction of preoperative radiotherapy in MLS</intervention_name>
    <description>A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age above or equal to 18 years

          2. Biopsy proven MLS (including the reciprocal chromosomal translocation
             t(12;16)(q13;p11); A the primary sarcoma in case of non-metastatic disease for
             management is with curative intent (regimen to be chosen = 18 x 2 GY) B in case of
             oligometastatic patients, the metastasis may also be irradiated to a dose of 36 GY in
             order to postpone the time interval to next systemic chemotherapy. These patients are
             usually not operated upon and the total dose may also be reached in 12 times 3 Gy,
             for convenience purposes (see paragraph 10 for radiobiological considerations).

          3. ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) 0-2

          4. Patients must be able (physically, mentally and socially) to complete a series of RT,
             followed by an observation period of 4-6 weeks and undergo surgery.

          5. Written informed consent

        Exclusion Criteria:

          1. Prior radiotherapy to the target area.

          2. Anticoagulant medication of any kind; especially Ascal®(and derivates), coumarines
             (Sintrom® and Marcoumar®), all heparin and heparin-like formulations. (Note: this
             exclusion criterion only applies for patients consenting to the translational
             research part of the study; patients on anticoagulant medication as described above
             may take part in the dose reduction part of the study, but the repeat biopsies may
             not be taken.)

          3. Pregnancy -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rick Haas, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rick Haas, MD,Phd</last_name>
    <phone>+31 20 5129111</phone>
    <email>r.haas@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Scholten, MD,PhD</last_name>
    <phone>+31205129111</phone>
    <email>a.scholten@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>MA 02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth Healey-Baldini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>MA 02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth Healey-Baldini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth Pras, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Piet van den Ende, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud umc</name>
      <address>
        <city>NIjmegen</city>
        <zip>6225GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Petra Braam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-310</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oyvind Bruland, Msc, MD, PhD</last_name>
      <phone>+ 47 22 93 40 00</phone>
      <email>oyvind.bruland@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aisha Miah, MCRP, FRCR, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Aisha Miah, MCRP, FRCR, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 19, 2016</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Myxoid liposarcoma</keyword>
  <keyword>Soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
